RenovoRx (RNXT) to Release Earnings on Monday

RenovoRx (NASDAQ:RNXT) will likely be posting its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect RenovoRx to post earnings of ($0.08) per share and revenue of $0.42 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 9:30 AM ET.

RenovoRx Price Performance

NASDAQ RNXT opened at $1.13 on Friday. The business’s fifty day moving average is $0.95 and its 200-day moving average is $1.01. The stock has a market capitalization of $41.41 million, a price-to-earnings ratio of -3.14 and a beta of 1.34. RenovoRx has a one year low of $0.70 and a one year high of $1.45.

Analysts Set New Price Targets

RNXT has been the subject of a number of research analyst reports. JonesTrading upgraded shares of RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. Ascendiant Capital Markets increased their target price on RenovoRx from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. Finally, Wall Street Zen upgraded RenovoRx from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, RenovoRx has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RNXT. XTX Topco Ltd boosted its stake in RenovoRx by 58.6% during the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after buying an additional 18,525 shares during the period. Geode Capital Management LLC increased its stake in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after acquiring an additional 31,730 shares during the last quarter. Bleichroeder LP raised its holdings in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of RenovoRx in the 2nd quarter valued at about $98,000. Finally, Citadel Advisors LLC bought a new stake in shares of RenovoRx during the 3rd quarter valued at about $154,000. Institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.